301 related articles for article (PubMed ID: 29543939)
1. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors.
Singh S; Chan DL; Moody L; Liu N; Fischer HD; Austin PC; Segelov E
JAMA Oncol; 2018 Apr; 4(4):583-585. PubMed ID: 29543939
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
3. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
4. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
5. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
6. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of gastroenteropancreatic neuroendocrine tumours.
Fraenkel M; Kim MK; Faggiano A; Valk GD
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):691-703. PubMed ID: 23582913
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
9. [Surgical treatments for gastroenteropancreatic neuroendocrine tumor (GEP-NET)].
Aoki T; Kokudo N
Nihon Shokakibyo Gakkai Zasshi; 2014 Dec; 111(12):2272-9. PubMed ID: 25482902
[No Abstract] [Full Text] [Related]
10. Aggressive gastro-entero-pancreatic neoplasms.
Coriat R
Ann Endocrinol (Paris); 2019 Jun; 80(3):185-186. PubMed ID: 31064660
[No Abstract] [Full Text] [Related]
11. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms.
Attili F; Capurso G; Vanella G; Fuccio L; Delle Fave G; Costamagna G; Larghi A
Dig Liver Dis; 2014 Jan; 46(1):9-17. PubMed ID: 23731843
[TBL] [Abstract][Full Text] [Related]
12. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
Singh S; Moody L; Chan DL; Metz DC; Strosberg J; Asmis T; Bailey DL; Bergsland E; Brendtro K; Carroll R; Cleary S; Kim M; Kong G; Law C; Lawrence B; McEwan A; McGregor C; Michael M; Pasieka J; Pavlakis N; Pommier R; Soulen M; Wyld D; Segelov E;
JAMA Oncol; 2018 Nov; 4(11):1597-1604. PubMed ID: 30054622
[TBL] [Abstract][Full Text] [Related]
13. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
[No Abstract] [Full Text] [Related]
14. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study.
Zhang X; Ma L; Bao H; Zhang J; Wang Z; Gong P
BMC Endocr Disord; 2014 Jul; 14():54. PubMed ID: 25001493
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
16. Surgical management of neuroendocrine tumors.
Tamburrino D; Spoletini G; Partelli S; Muffatti F; Adamenko O; Crippa S; Falconi M
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):93-102. PubMed ID: 26971846
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic neuroendocrine tumors: Role of surgery.
Sauvanet A
Ann Endocrinol (Paris); 2019 Jun; 80(3):175-181. PubMed ID: 31079831
[TBL] [Abstract][Full Text] [Related]
18. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
[TBL] [Abstract][Full Text] [Related]
20. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]